Clinical study on BMY-28100

We performed clinical studies on BMY-28100, a new oral cephalosporin, with the following results. 1) Clinical efficacy : BMY-28100 750mg or 1500mg/day was given to 1 patient with acute suppurative tonsillitis, 3 patients with acute bronchitis, 1 with infection complicating pulmonary emphysema, 1 with pneumonia complicating chronic bronchitis, 1 with bronchiectasis, 3 with chronic bronchitis, 3 with bacterial pneumonia, and 1 with infection complicating bronchial asthma, for 2-13 days. Clinical response was excellent in 1, good in 4, fair in 3 and poor in 4 patients, while 1 patient was unevaluable. Clinical efficacy was 41.7%. 2) Bacteriological efficacy : Seven strains (3 of Haemophilus influenzae, 1 of Streptococcus pneumoniae, 1 of Enterobacter cloacae, 1 of Pseudomonas aeruginosa and 1 of Serratia marcescens) were isolated. One strain of E, cloacae was eradicated. One strain of S. pneumoniae was eradicated, but changed to Enterobacter aerogenes, and one strain of S. marcescens changed to H. influenzae and Klebsiella pneumoniae. Other isolated strains were not eradicated. Bacteriological efficacy was 50%. 3) Side effects and laboratory findings : Skin eruption as a side effect was observed in one patient, but no abnormal labolatory findings were observed.